Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Daily Prophylaxis Dose Anticoagulation With a Factor Xa Inhibitor (Apixaban) in Patients With Sickle Cell Disease

NCT02179177 is registered in ClinicalTrials.gov with Nirmish Shah as lead sponsor.

NCT NCT02179177
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02179177 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Daily Prophylaxis Dose Anticoagulation With a Factor Xa Inhibitor (Apixaban) in Patients With Sickle Cell Disease
Lead sponsor
Nirmish Shah
Phase
Phase 3
Overall status
Terminated
Start date
January 31, 2015
Completion date
September 3, 2017
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

reduction in hospitalizations, sickle cell disease, vaso-occlusive crisis